Merck, Schering-Plough End Vytorin Investigation

By Shannon Henson

Law360, New York (July 15, 2009, 12:00 AM ET) -- In a settlement, Merck & Co. and Schering-Plough Corp. have agreed to reimburse 35 states and the District of Columbia for the costs associated with investigating a delay in the companies' release of negative results of a clinical trial of the jointly marketed cholesterol treatment Vytorin.

The deal announced Wednesday by the states and the companies also calls for Merck and Schering-Plough to obtain preapproval from the U.S. Food and Drug Administration for all direct-to-consumer television advertisements and to comply with FDA suggestions to modify drug...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles